Results 81 to 90 of about 937 (121)

The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective Dosing. [PDF]

Clin Pharmacokinet
Wright DFB, Hishe HZ, Dalbeth N, Horne A, Drake J, Haslett J, Stamp LK.   +6 more
europepmc   +1 more source

Pacific community's perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients. [PDF]

Int J Equity Health
Ofanoa S, Ofanoa M, Tu'akoi S, Lutui H, Heather M, Goodyear-Smith F.   +5 more
europepmc   +1 more source

Comparison of pharmacokinetic and pharmacodynamic properties of allopurinol and benzbromarone in a quail model of hyperuricemia. [PDF]

J Vet Sci
Zheng S, Bu Y, Li S, Chen N.
europepmc   +1 more source

Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies. [PDF]

Front Endocrinol (Lausanne)
Li X, Chen Z, Zhang Y, Fan C, Chen L, Xu X, Chang J, Qiang W, Jiang H, Liu C.   +9 more
europepmc   +1 more source

2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients. [PDF]

Int J Rheum Dis
Sun M, Lyu Z, Wang C, Li Y, Zhao D, Ran X, Chen H, Su B, Chang X, Liu P, Yan D, Jiang X, Chen K, Shao J, Teng X, Yao Y, Li Y, Chen Y, Cheng J, Cheng Z, Liu Z, Liu F, Li X, Yin H, Liu C, Lin HY, Chen Y, Tsai WC, Yip RML, Li C, Zhao J.   +30 more
europepmc   +1 more source

An Analysis of Cost Variation Among Drugs Available in the Indian Market for the Treatment of Chronic Bone-Related Ailments. [PDF]

Cureus
Jayachandran M, Geevarughese NM, Palatty PL, Baliga-Rao MP, Sacheendran D, Baliga MS.   +5 more
europepmc   +1 more source

Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States. [PDF]

Adv Ther
Kragh N, Worsfold A, Oladapo A, Gao E, Sethi S, Swallow E.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Study on methodology of detecting illegally added chemical agents of gout suppressants

Pharmaceutical Care and Research, 2012
ShaoMin ZHANG, Bin CHEN, ShanWen LING, YueLin YU   +3 more
exaly   +2 more sources

NLRP3 inflammasome inhibitor cucurbitacin B suppresses gout arthritis in mice

Journal of Molecular Endocrinology, 2021
Gouty arthritis is a common inflammatory disease characterized by monosodium urate (MSU) crystal-induced nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome activation with upregulated caspase 1 protease and IL-1β in macrophages.
Ying, Xue, Ran, Li, Ping, Fang, Zheng-Qin, Ye, Yong, Zhao, Yun, Zhou, Ke-Qin, Zhang, Ling, Li   +7 more
openaire   +2 more sources

Opposite effects of cations in enhancing and suppressing nucleation in the pathological crystallization of gout

CrystEngComm, 2021
“Opposite effects” were shown by cations, enhancing nucleation followed by suppressing nucleation at physiological pH and ionic strength.
Anqi Da, Aijun Ren, Rong Cheng, Xingde Zhang, Yonglan Pan, Chunyan Ou, Tingming Fu, Yonghai Liu   +7 more
openaire   +1 more source